Viimeisimmät artikkelit
- Desentum to present clinical results of investigational birch pollen allergy vaccine DM-101PX and scientific discoveries about peanut allergy at the world’s largest allergy congress
- Desentum reports strong safety and immunological data from Phase 1 clinical study with investigational birch pollen allergy vaccine DM-101PX
- Ilmoitus osakkeiden siirtymisestä Desentum Oy:n osakkeenomistajille
- Pekka Mattila conferred as Honorary Doctor at the University of Eastern Finland
- Desentum raised 12 million euros for advancing allergy vaccine development
Viimeisimmät kommentit
No comments to show.